Please use this identifier to cite or link to this item: https://doi.org/10.46883/2023.25920992
Title: Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma
Authors: Daniel V. T. Catenacci
Yoon-Koo Kang
Hope E. Uronis
Keun-Wook Lee
Matthew C. H. Ng 
Peter C. Enzinger
Se Hoon Park
Philip J. Gold
Jill Lacy
Howard S. Hochster
Sang Cheul Oh
Yeul Hong Kim
Kristen A. Marrone
Ronan J. Kelly
Rosalyn A. Juergens
Jong Gwang Kim
Thierry Alcindor
Sun Jin Sym
Eun-Kee Song
Cheng Ean Chee 
Yee Chao
Sunnie Kim
Do-Youn Oh
Jennifer Yen
Justin I. Odegaard
Errin Lagow
Daner Li
Jichao Sun
Patrick Kaminker
Paul A. Moore
Minori Koshiji Rosales
Haeseong Park
Issue Date: 12-Apr-2023
Publisher: MJH Life Sciences
Citation: Daniel V. T. Catenacci, Yoon-Koo Kang, Hope E. Uronis, Keun-Wook Lee, Matthew C. H. Ng, Peter C. Enzinger, Se Hoon Park, Philip J. Gold, Jill Lacy, Howard S. Hochster, Sang Cheul Oh, Yeul Hong Kim, Kristen A. Marrone, Ronan J. Kelly, Rosalyn A. Juergens, Jong Gwang Kim, Thierry Alcindor, Sun Jin Sym, Eun-Kee Song, Cheng Ean Chee, Yee Chao, Sunnie Kim, Do-Youn Oh, Jennifer Yen, Justin I. Odegaard, Errin Lagow, Daner Li, Jichao Sun, Patrick Kaminker, Paul A. Moore, Minori Koshiji Rosales, Haeseong Park (2023-04-12). Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma. ONCOLOGY (3704) : 176-183. ScholarBank@NUS Repository. https://doi.org/10.46883/2023.25920992
Source Title: ONCOLOGY
URI: https://scholarbank.nus.edu.sg/handle/10635/239260
ISSN: 0890-9091
DOI: 10.46883/2023.25920992
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Catenacci_Oncology 2023+Suppl.pdf2.31 MBAdobe PDF

CLOSED

None

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.